Teprotumumab, a human anti-IGF1R monoclonal antibody, has been demonstrated to be detrimental to the glycolytic phenotype in experiments with graves’ orbitopathy orbital fibroblasts (GO OFs) from patients with TAO. This evidence concerns the gene IGF1R and thromboangiitis obliterans.